Predictive Historical Financial Ratios
| POAI Stock | USD 1.60 0.09 5.33% |
Predictive Oncology is promptly reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.95, Invested Capital of 0.0, Average Payables of 769.1 K or Stock Based Compensation To Revenue of 0.38 will help investors to properly organize and evaluate Predictive Oncology financial condition quickly.
Predictive |
About Predictive Financial Ratios Analysis
Predictive OncologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Predictive Oncology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Predictive financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Predictive Oncology history.
Predictive Oncology Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Predictive Oncology stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Predictive Oncology sales, a figure that is much harder to manipulate than other Predictive Oncology multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Predictive Oncology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Capex To Revenue is decreasing as compared to previous years. The Predictive Oncology's current Net Debt To EBITDA is estimated to increase to 0.42, while Price To Sales Ratio is projected to decrease to 8.11.
| 2022 | 2024 | 2025 (projected) | Payables Turnover | 0.54 | 0.43 | 0.31 | Days Of Inventory On Hand | 311.08 | 326.9 | 387.01 |
Predictive Oncology fundamentals Correlations
Click cells to compare fundamentals
Predictive Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Predictive Oncology fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 6.99 | 36.77 | 14.89 | 7.42 | 8.53 | 8.11 | |
| Ptb Ratio | 3.31 | 1.3 | 1.03 | 1.6 | 1.44 | 1.37 | |
| Days Sales Outstanding | 74.87 | 91.0 | 80.3 | 68.42 | 78.69 | 122.35 | |
| Book Value Per Share | 4.42 | 14.68 | 5.96 | 2.06 | 1.85 | 1.95 | |
| Free Cash Flow Yield | (1.17) | (1.44) | (0.25) | (0.57) | (1.02) | (1.23) | |
| Operating Cash Flow Per Share | (20.51) | (4.45) | (3.39) | (3.29) | (2.96) | (3.1) | |
| Capex To Depreciation | 0.35 | 0.72 | 0.36 | 0.41 | 0.47 | 0.45 | |
| Pb Ratio | 3.31 | 1.3 | 1.03 | 1.6 | 1.44 | 1.37 | |
| Ev To Sales | 11.13 | 17.54 | 0.34 | 4.12 | 4.74 | 4.5 | |
| Free Cash Flow Per Share | (21.12) | (4.8) | (3.52) | (3.36) | (3.02) | (3.18) | |
| Roic | (0.11) | (0.32) | (0.97) | (1.26) | (1.45) | (1.38) | |
| Inventory Turnover | 1.54 | 1.26 | 1.17 | 1.28 | 1.16 | 1.01 | |
| Net Income Per Share | (63.1) | (7.16) | (9.92) | (3.48) | (3.13) | (3.29) | |
| Days Of Inventory On Hand | 236.32 | 290.55 | 311.08 | 284.26 | 326.9 | 387.01 | |
| Payables Turnover | 0.17 | 0.33 | 0.48 | 0.54 | 0.43 | 0.31 | |
| Sales General And Administrative To Revenue | 8.27 | 7.69 | 7.38 | 5.3 | 6.09 | 5.79 | |
| Research And Ddevelopement To Revenue | 1.88 | 0.22 | 0.21 | 0.11 | 0.0952 | 0.0904 | |
| Capex To Revenue | 0.29 | 0.68 | 0.32 | 0.17 | 0.15 | 0.18 | |
| Cash Per Share | 1.14 | 10.28 | 6.05 | 2.17 | 2.5 | 2.38 | |
| Pocfratio | (0.71) | (4.28) | (1.81) | (1.0) | (0.9) | (0.95) | |
| Capex To Operating Cash Flow | (0.0294) | (0.0788) | (0.0385) | (0.0229) | (0.0206) | (0.0217) | |
| Pfcf Ratio | (0.69) | (3.97) | (1.74) | (0.98) | (0.88) | (0.93) | |
| Days Payables Outstanding | 1.1K | 765.77 | 681.76 | 771.65 | 887.4 | 843.03 | |
| Income Quality | 0.47 | 0.62 | 0.48 | 0.94 | 0.85 | 0.46 | |
| Roe | (14.27) | (0.49) | (1.66) | (1.69) | (1.94) | (2.04) | |
| Ev To Operating Cash Flow | (1.14) | (2.04) | (0.042) | (0.56) | (0.5) | (0.53) | |
| Pe Ratio | (0.23) | (2.66) | (0.62) | (0.94) | (0.85) | (0.89) | |
| Return On Tangible Assets | (5.51) | (0.6) | (1.42) | (0.99) | (0.89) | (0.93) | |
| Ev To Free Cash Flow | (1.11) | (1.89) | (0.0404) | (0.54) | (0.49) | (0.51) | |
| Earnings Yield | (4.31) | (0.38) | (1.62) | (1.06) | (1.22) | (1.28) | |
| Intangibles To Total Assets | 0.48 | 0.25 | 0.009865 | 0.0175 | 0.0201 | 0.0191 | |
| Net Debt To E B I T D A | (0.45) | 2.25 | 1.57 | 0.45 | 0.4 | 0.42 | |
| Current Ratio | 0.16 | 9.09 | 6.02 | 2.55 | 2.3 | 1.36 | |
| Tangible Book Value Per Share | (5.97) | 10.73 | 5.89 | 2.0 | 1.8 | 1.89 | |
| Receivables Turnover | 4.87 | 4.01 | 4.55 | 5.33 | 6.13 | 7.03 | |
| Shareholders Equity Per Share | 4.42 | 14.68 | 5.96 | 2.06 | 1.85 | 1.95 |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.83) | Revenue Per Share | Quarterly Revenue Growth (0.49) | Return On Assets | Return On Equity |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.